Apolipoprotein E and the risk of breast cancer in African-American and non-Hispanic white women: A review

Oncology

Volumn 66, Issue 2, 2004, Pages 79-93

  Moore, Rhonda J ^a,c   Chamberlain, Robert M ^a   Khuri, Fadlo R ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apolipoprotein E; Breast cancer; Epidemiology; Ethnicity; Lipids; Review; Risk factors

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL FACTOR; ESTROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN; HORMONE; INSULIN; LIPID; VERY LOW DENSITY LIPOPROTEIN;

AFRICAN AMERICAN; BREAST CARCINOMA; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CELL REGENERATION; DIET; DISEASE ASSOCIATION; ETHNOLOGY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; NUTRITION; OBESITY; PRIORITY JOURNAL; PROTECTION; REVIEW; RISK ASSESSMENT; SEX RATIO; STATISTICAL DISTRIBUTION; TUMOR SUPPRESSOR GENE;

AFRICAN AMERICANS; AGE FACTORS; APOLIPOPROTEINS E; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOOD HABITS; GENES, TUMOR SUPPRESSOR; HUMANS; INCIDENCE; INSULIN RESISTANCE; LIPIDS; MUTATION; OBESITY; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 2342645999     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077433     Document Type: Review

References (150)

1. Mahley RW, Rall SC Jr: Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-537.
2. Roses AD: A model for susceptibility polymorphisms for complex diseases: Apolipoprotein E and Alzheimer disease. Neurogenetics 1997;1:3-11.
3. Utermann G: Apolipoprotein E polymorphism in health and disease. Am Heart J 1987;113:433-440.
4. Davignon J, Gregg RE, Sing SF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1998;8:1-21.
5. Sing CF, Davignon J: Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985;7:268-285.
6. Williams DL, Dawson PA, Newman TC, Rudel LL: Apolipoprotein E synthesis in peripheral tissues of nonhuman primates. J Biol Chem 1985;260:2444-2451.
7. Crews DE, Bindon JR, Kamboh MI: Apolipoprotein polymorphisms and phenotypic variability in American Samoans: Preliminary data. Am J Human Biol 1993;5:39-48.
8. Driscoll DM, Getz GS: Extrahepatic synthesis of apolipoprotein E. J Lipid Res 1984:25: 1368-1379.
9. Ikewaki K, Zech LA, Brewer HB Jr, Rader DJ: Comparative in vivo metabolism of apolipoproteins E2 and E4 in heterozygous apoE2/4 subjects. J Lab Clin Med 2002;140:369-374.
10. Reardon CA: Differential metabolism of apolipoprotein E isoproteins. J Lab Clin Med 2002;140:301-302.
11. Mahley RW: Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-630.
12. Utermann G, Kindermann I, Kaffarnik H, Steinmetz A: Apolipoprotein E phenotypes and hyperlipidemia. Hum Genet 1984:62:232-236.
13. Bedlack RS, Strittmatter WJ, Morgenlander JC: Apolipoprotein E and neuromuscular disease: A critical review of the literature. Arch Neurol 2000;57:1561-1565.
14. Daugherty A: Atherosclerosis: Cell biology and lipoproteins. Curr Opin Lipidol 2002;13:453-455.
15. Bach-Ngohou K, Ouguerram K, Nazih H, Maugere P, Ripolles-Piquer B, Zair Y, Frenais R, Krempf M, Bard JM: Apolipoprotein E kinetics: Influence of insulin resistance and type 2 diabetes. Int J Obes Relat Metab Disord 2002;26:1451-1458.
16. Howard BV, Gidding SS, Liu K: Association of apolipoprotein E phenotype with plasma lipoprotein in African-American and white young adults. Am J Epidemiol 1998;48:859-868.
17. Wilson RS, Bienias JL, Berry-Kravis E, Evans DA, Bennett DA: The apolipoprotein E varepsilon 2 allele and decline in episodic memory. J Neurol Neurosurg Psychiatry 2002;73:672-677.
18. Raber J, Wong D, Yu GQ, Buttini M, Mahley RW, Pitas RE, Mucke L: Apolipoprotein E and cognitive performance. Nature 2000;23;404:352-354.
19. Alafuzoff I, Helisalmi S, Mannermaa A, Soininen H: Severity of cardiovascular disease, apolipoprotein E genotype, and brain pathology in aging and dementia. Ann NY Acad Sci 2000;903:244-251.
20. Lovestone S, Reynolds CH: The phosphorylation of tau: A critical stage in neurodevelopmental and neurodegenerative processes. Neuroscience 1997;78:309-324.
21. Pablos-Mendez A, Mayeux R, Ngai C, Shea S, Berglund L: Association of apo E polymorphism with plasma lipid levels in a multiethnic elderly population. Arterioscler Thromb Vasc Biol 1997;17:3534-3541.
22. McCarron MO, Hoffmann KL, DeLong DM, Gray L, Saunders AM, Alberts MJ: Intracerebral hemorrhage outcome: Apolipoprotein E genotype, hematoma, and edema volumes. Neurology 1999;53:2176-2179.
23. Smith JD: Apolipoproteins and aging: Emerging mechanisms. Ageing Res Rev 2002;1:345-365.
24. Yanagisawa M, Planel E, Ishiguro K, Fujita SC: Starvation induces tau hyperphosphorylation in mouse brain: Implications for Alzheimer's disease. FEBS Lett 1999;461:329-333.
25. Kamboh MI, DeKosky S: Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease. Ann Neurol 1995;38:967-969.
26. Carr FJ, McBride MW, Carswell HV, Graham D, Strahorn P, Clark JS, Charchar FJ, Dominiczak AF: Genetic aspects of stroke: Human and experimental studies. J Cereb Blood Flow Metab 2002;22:767-773.
27. Masterman T, Zhang Z, Hellgren D, Salter H, Anvret M, Lilius L, Lannfelt L, Hillert J: APOE genotypes and disease severity in multiple sclerosis. Mult Scler 2002;8:98-103.
28. Shua-Haim JR: The APO E ε4 allele and the risk of Alzheimer disease among African Americans, Whites and Hispanics. J Am Geriatr Soc 1998;46:798-799.
29. Gearing M, Rebeck GW, Hyman B, Tigges J, Mirra SS: Neuropathology and apolipoprotein E profile of aged chimpanzees: Implications for Alzheimer disease. Proc Natl Acad Sci USA 1994;91:9382-9386.
30. Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, Raskind MA: Increased CSF cortisol in AD is a function of APOE genotype. Neurology 2001;56:1094-1098.
31. Ohkubo N, Mitsuda N, Tamatani M, Yamaguchi A, Lee YD, Ogihara T, Vitek MP, Tohyama M: Apolipoprotein E4 stimulates cAMP response element-binding protein transcriptional activity through the extracellular signal-regulated kinase pathway. J Biol Chem 2001;276:3046-3053.
32. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, van Belle G, Jolley L, Larson EB: Dementia and Alzheimer disease incidence: A prospective cohort study. Arch Neurol 2002;59:1737-1746.
33. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356.
34. Blum A, Cannon R: Effects of oestrogens and selective oestrogen receptor modulators on serum lipoproteins and vascular function. Curr Opin Lipidol 1998;9:575-586.
35. Garry PJ, Baumgartner PN, Brodie SG, Montoya GD, Liang HC, Lindeman RD, Williams TM: Estrogen replacement therapy, serum lipids, and polymorphism of the apolipoprotein E gene. Clin Chem 1999;45:1214-1223.
36. Corder EH, Saunders AM, Risch NJ: Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7:180-183.
37. Pluta R: The role of apolipoprotein E in the deposition of β-amyloid peptide during ischemia-reperfusion brain injury: A model of early Alzheimer's disease. Ann NY Acad Sci 2000;903:324-334.
38. Buttini M, Yu GQ, Shockley K, Huang Y, Jones B, Masliah E, Mallory M, Yeo T, Longo FM, Mucke L: Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J Neurosci 2002;22:10539-10548.
39. Kitagawa K, Matsumoto M, Hori M, Yanagihara T: Neuroprotective effect of apolipoprotein E against ischemia. Ann NY Acad Sci 2002;977:468-475.
40. Dodart JC, Bales KR, Johnstone EM, Little SP, Paul SM: Apolipoprotein E alters the processing of the beta-amyloid precursor protein in APP(V717F) transgenic mice. Brain Res 2002; 955:191-199.
41. Hong M, Lee VM: Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997; 272:19547-19553.
42. Hartman RE, Laurer H, Longhi L, Bales KR, Paul SM, McIntosh TK, Holtzman DM: Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. J Neurosci 2002;22:10083-10087.
43. Hoy A, Leininger-Muller B, Jolivalt C, Siest G: Effect of apolipoprotein E on cell viability in a human neuroblastoma cell line: Influence of oxidation and lipid-association. Neurosci Lett 2000;285173-285176.
44. Niemi M, Hakkinen T, Karttunen TJ, Eskelinen S, Kervinen K, Savolainen MJ, Lehtola J, Makela J, Yla-Herttuala S, Kesaniemi YA: Apolipoprotein E and colon cancer. Expression in normal and malignant human intestine and effect on cultured human colonic adenocarcinoma cells. Eur J Intern Med 2002;13:37-43.
45. Watson MA, Gay L, Stebbings WS, Speakman CT, Bingham SA, Loktionov A: Apolipoprotein E gene polymorphism and colorectal cancer: Gender-specific modulation of risk and prognosis. Clin Sci (Lond) 2003;104:537-545.
46. Moysich KB, Freudenheim JL, Baker JA, Ambrosone CB, Bowman ED, Schisterman EF, Vena JE, Shields PG: Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. Mol Carcinog 2000;27:2-9.
47. Liberopoulos E, Karabina SA, Tselepis A, Bairaktari E, Nicolaides C, Pavlidis N, Elisaf M: Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes? Oncology 2002;62:115-120.
48. Vijg J, Perls T, Franceschi C, van Orsouw NJ: BRCA1 gene sequence variation in centenarians. Ann NY Acad Sci 2001;928:85-96.
49. Kervinen K, Sodervik H, Makela J, Lehtola J, Niemi M, Kairaluoma MI, Kesaniemi YA: Is the development of adenoma and carcinoma in proximal colon related to apolipoprotein E phenotype? Gastroenterology 1996;110:1785-1790.
50. Liestol K, Kvittingen EA, Rootwelt H, Dunlop O, Goplen AK, Pedersen JC, Brorson SH, Borresen-Dale AL, Myrvang B, Maehlen J: Association between apolipoprotein E genotypes and cancer risk in patients with acquired immunodeficiency syndrome. Cancer Detect Prev 2000;24:496-499.
51. Butler WJ, Ryan P, Roberts-Thomson IC: Metabolic genotypes and risk for colorectal cancer. J Gastroenterol Hepatol 2001;16:631-635.
52. Zetterberg H, Palmer M, Ricksten A, Poirier J, Palmqvist L, Rymo L, Zafiropoulos A, Arvanitis DA, Spandidos DA, Blennow K: Influence of the apolipoprotein E epsilon4 allele on human embryonic development. Neurosci Lett 2002;324:189-192.
53. Niemi M, Kervinen K, Kiviniemi H, Lukkarinen O, Kyllonen AP, Apaja-Sarkkinen M, Savolainen MJ, Kairaluoma MI, Kesaniemi YA: Apolipoprotein E phenotype, cholesterol and breast and prostate cancer. J Epidemiol Community Health 2000;54:978-979.
54. Haapala K, Lehtimaki T, Ilveskoski E, Koivisto PA: Apolipoprotein E is not linked to locally recurrent hormone-refractory prostate cancer. Prostate Cancer Prostatic Dis 2000;3:107-109.
55. Zunarelli E, Nicoll JA, Migaldi M, Trentini GP: Apolipoprotein E polymorphism and breast carcinoma: Correlation with cell proliferation indices and clinical outcome. Breast Cancer Res Treat 2000;63193-63198.
56. Shinomiya S, Sasaki J, Kiyohara C, Tsuji E, Inoue H, Marugame T, Handa K, Hayabuchi H, Hamada H, Eguchi H, Fukushima Y, Kono S: Apolipoprotein E genotype, serum lipids, and colorectal adenomas in Japanese men. Cancer Lett 2001;164:33-40.
57. Zunarelli E, Nicoll JA, Trentini GP: Apolipoprotein E polymorphism and central nervous system tumors: Correlation with cell proliferation indices and clinical outcome. Clin Neuropathol 2000;19:1-6.
58. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 2002;2:23-47.
59. American Cancer Society: Cancer Facts and Figures 2003. Atlanta, American Cancer Society, 2003.
60. Brawley OW: Some perspective on black-white cancer statistics. CA Cancer J Clin 2002;52:322-325.
61. Anderson WF, Chatterjee N, Ershler WB, Brawley OW: Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002;76:27-36.
62. Joslyn S, West M: Racial differences in breast carcinoma survival. Cancer 2000;88:114-123.
63. Cross CK, Harris J, Recht A: Race, socioeconomic status, and breast carcinoma in the US: What have we learned from clinical studies. Cancer 2002;95:1988-1999.
64. Barnett JB, Woods MN, Rosner B, McCormack C, Longcope C, Houser RF Jr, Gorbach SL: Sex hormone levels in premenopausal African-American women with upper and lower body fat phenotypes. Nutr Cancer 2001;41:47-56.
65. Harris JR, Lippman ME, Morrow M, Osborne KC: Diseases of the Breast. Philadelphia, Lippincott Williams & Wilkins, 2000.
66. Eley J, Hill H, Chen V, Austin DF, Wesley MN, Muss HB, et al: Racial differences in survival from breast cancer. JAMA 1994;272:947-954.
67. McCarthy EP, Burns RB, Coughlin SS, Freund KM, Rice J, Marwill SL, et al: Mammography use helps to explain differences in breast cancer stage at diagnosis between older black and white women. Ann Intern Med 1998;128:729-736.
68. Aziz H, Hussain F, Sohn C, Mediavillo R, Saitta A, et al: Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Oncol 1999;22:436-440.
69. Pathak DR, Osuch JR, He J: Breast carcinoma etiology: Current knowledge and new insights into the effects of reproductive and hormonal risk factors in black and white populations. Cancer 2000;88(suppl 5):1230-1238.
70. Apter D, Reinila M, Vihko R: Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. Int J Cancer 1989;44:783-787.
71. Wojcik BE, Spinks MK, Optenberg SA: Breast carcinoma survival analysis for African American and white women in an equal-access health care system. Cancer 1998;82:1310-1318.
72. Li CI, Malone KE, Daling JR: Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 2003;163:49-56.
73. Forshee RA, Storey ML, Ritenbaugh C: Breast cancer risk and lifestyle differences among premenopausal and postmenopausal African-American women and white women. Cancer 2003;97(1 suppl):280-288.
74. Rock CL, Demark-Wahnefried W: Can lifestyle modification increase survival in women diagnosed with breast cancer? J Nutr 2002; 132(suppl 11):3504S-3507S.
75. Stoll BA: Affluence, obesity, and breast cancer. Breast J 2000;6:146-149.
76. Berkman LF, Glass T, Brissette I, Seeman TE: From social integration to health: Durkheim in the new millennium. Soc Sci Med 2000;51:843-857.
77. Williams DR, Collins C: Racial residential segregation: A fundamental cause of racial disparities in health. Public Health Rep 2001;116:404-416.
78. Madan AK, Barden CB, Beech B, Fay K, Sintich M, Beech DJ: Self-reported differences in daily raw vegetable intake by ethnicity in a breast screening program. J Natl Med Assoc 2002;94:894-900.
79. Ruckdeschel JC: Update in oncology. Ann Intern Med 1999;131:760-797.
80. Spiegel D: A 43-year-old woman coping with cancer. JAMA1999;282:371-338.
81. Haimov-Kochman R, Lavy Y, Hochner-Celinkier D: Review of risk factors for breast cancer - What's new? Harefuah 2002;141:702-708, 761.
82. Freeman HP, Wasfie TJ: Cancer of the breast in poor black women. Cancer 1989;15;63:2562-2569.
83. Freedman TG: 'Why don't they come to Pike Street and ask us'?: Black American women's health concerns. Soc Sci Med 1998;47:941-947.
84. Bernstein JL, Lapinski R, Lynch C, Holford T, Thompson WD: Factors influencing mortality among young women with second primary breast carcinoma. Cancer 2002;95:2051-2058.
85. Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR: Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women. Int J Cancer 2002;98:118-127.
86. Bradley CJ, Given CW, Roberts C: Disparities in cancer diagnosis and survival. Cancer 2001;91:178-188.
87. Dignam JJ: Differences in breast cancer prognosis among African-American and Caucasian women. CA Cancer J Clin 2000;50:50-64.
88. Hoffman-Goetz L, Breen NL, Meissner H: The impact of social class on the use of cancer screening within three racial/ethnic groups in the United States. Ethn Dis 1998;8:43-51.
89. Taylor SE, Repetti RL, Seeman T: Health psychology: What is an unhealthy environment and how does it get under the skin? Annu Rev Psychol 1997;48:411-447.
90. Lawrence DA, Harry GJ: Environmental stressors and neuroimmunotoxicological processes. Brain Behav Immun 2000;14:231-238.
91. Heijnen CJ: Who believes in communication? Norman Cousins Lecture 1999. Brain Behav Immun 2000;14:2-9.
92. Sapolsky R: Why Zebra's Don't Get Ulcers. New York, Freeman, 1994.
93. Li CY, Little JB, Hu K, Zhang W, Zhang L, Dewhirst MW, Huang Q: Persistent genetic instability in cancer cells induced by non-DNA-damaging stress exposures. Cancer Res 2001;61:428-432.
94. McEwen BS: Protective and damaging effects of stress mediators. N Engl J Med 1998;338:171-199.
95. Eskandari F, Sternberg EM: Neural-immune interactions in health and disease. Ann NY Acad Sci 2002;966:20-27.
96. Bernstein L, Teal CR, Joslyn S, Wilson J: Ethnicity-related variation in breast cancer risk factors. Cancer 2003;97(1 suppl):222-229.
97. Wu AH: Diet and breast carcinoma in multiethnic populations. Cancer 2000;88:1239-1244.
98. Hunter DJ, Spiegelman D, Adami HO, et al: Cohort studies of fat intake and breast cancer - A pooled analysis. N Engl J Med 1996;334:356-361.
99. Dorgan JF, Hunsberger SA, McMahon RP, Kwiterovich PO Jr, Lauer RM, Van Horn L, Lasser NL, et al: Diet and sex hormones in girls: Findings from a randomized controlled clinical trial. J Natl Cancer Inst 2003;95:132-141.
100. Huang Z, Hankinson SE, Colditz GA, et al: Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;278:1407-1411.
101. Goldin BR, Adlercreutz H, Gorbach SL, et al: Estrogen excretion patterns and plasma levels in vegetarian and omnivorous women. N Engl J Med 1982;307:1542-1547.
102. Rose DP: Dietary fiber and breast cancer. Nutr Cancer 1990;13:1-8.
103. Stark AH, Switzer BR, Atwood JR, et al: Estrogen profiles in postmenopausal African-American women in a wheat bran fiber intervention study. Nutr Cancer 1998;31:138-142.
104. Sieri S, Krogh V, Muti P, Micheli A, Pala V, Crosignani P, Berrino F: Fat and protein intake and subsequent breast cancer risk in postmenopausal women. Nutr Cancer 2002;42:10-17.
105. Gorin SS, Jacobson J: Diet and breast cancer surveillance behaviors among Harlem women. Ann NY Acad Sci 2001;952:153-160.
106. Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC: Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002;23:1491-1496.
107. Rock CL, Demark-Wahnefried W: Nutrition and survival after the diagnosis of breast cancer: A review of the evidence. J Clin Oncol 2002;20:3302-3316.
108. Willett WC: Diet and breast cancer. J Intern Med 2001;249:395-411.
109. Hiatt RA, Friedman GD, Bawol RD, Ury HK: Breast cancer and serum cholesterol. J Natl Cancer Inst 1982;68:885-889.
110. Potischman N, McCulloch CE, Byers T, et al: Associations between breast cancer, plasma triglycerides, and cholesterol. Nutr Cancer 1991;15:205-215.
111. Sharma V, Sharma A: Serum cholesterol levels in carcinoma breast. Indian J Med Res 1991;94:193-196.
112. Tornberg SA, Holm LE, Cartensen JM: Breast cancer risk in relation to serum cholesterol, serum betal-lipoprotein, height, weight and blood pressure. Acta Oncol 1988;27:31-37.
113. Morris DL, Borhani NO, Fitzsimons E, et al: Serum cholesterol and cancer in the Hypertension Detection and Follow-Up Program. Cancer 1983;52:1754-1759.
114. Wingard DL, Criqui MH, Holdbook MJ, Barrett-Connor E: Plasma cholesterol and cancer morbidity and mortality in an adult community. J Chronic Dis 1984;37:401-406.
115. Vatten LJ, Foss OP: Total serum cholesterol and triglycerides and risk of breast cancer: A prospective study of 24,329 Norwegian women. Cancer Res 1990;50:2341-2346.
116. Bani IA, Williams CM, Boulter PS, Dickerson JW: Plasma lipids and prolactin in patients with breast cancer. Br J Cancer 1986;54:439-446.
117. Kumar K, Sachdanandam P, Arivazhagan R: Studies on the changes in plasma lipids and lipoproteins in patients with benign and malignant breast cancer. Biochemistry 1991;23:581-589.
118. Agurs-Collins T, Kim KS, Dunston GM, et al: Plasma lipid alterations in African-American women with breast cancer. J Cancer Res Clin Oncol 1998;124:186-190.
119. Kokoglu E, Karaarslan I, Karaarslan HM, Baloglu H: Alterations of serum lipids and lipoproteins in breast cancer. Cancer Lett 1994;82:175-178.
120. Zielinski CC, Stuller I, Rausch P, Muller C: Increased serum concentrations of cholesterol and triglycerides in the progression of breast cancer. J Cancer Res Clin Oncol 1988;114:514-518.
121. Kelly PT: Breast cancer risks: Some clinically useful approaches. Curr Womens Health Rep 2002;2:128-133.
122. Miller K: Estrogen and DNA damage: The silent source of breast cancer? J Natl Cancer Inst 2003;95:100-102.
123. Stoll BA: Premalignant breast lesions: Role for biological markers in predicting progression to cancer. Eur J Cancer 1999;35:693-697.
124. Foulkes WD, Hodgson SV (eds): Inherited Susceptibility to Cancer: Clinical, Predictive and Ethical Perspectives. Cambridge, Cambridge University Press, 1998.
125. Martin MB, Stoica A: Insulin-like growth factor-I and estrogen interactions in breast cancer. J Nutr 2002;132:3799S-3801S.
126. Stoll BA: Western nutrition and the insulin resistance syndrome: A link to breast cancer. Eur J Clin Nutr 1999;53:83-87.
127. Stoll BA: Oestrogen/insulin-like growth factor-I receptor interaction in early breast cancer: Clinical implications. Ann Oncol 2002;13:191-196.
128. Jernstrom H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, Pollak M, Narod SA: Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: Implications for premenopausal breast cancer risk. Mol Genet Metab 2001;72:144-154.
129. Newman LA, Theriault R, Clendinnin N, Jones D, Pierce L: Treatment choices and response rates in African-American women with breast carcinoma. Cancer 2003;97(1 suppl):246-252.
130. Peacock SL, White E, Daling JR, Voigt LF, Malone KE: Relation between obesity and breast cancer in young women. Am J Epidemiol 1999;149:339-346.
131. Galanis DJ, Kolonel LN, Lee J, Le Marchand L: Anthropometric predictors of breast cancer incidence and survival in a multi-ethnic cohort of female residents of Hawaii, United States. Cancer Causes Control 1998;9:217-224.
132. Mokbel K: Breast cancer prevention. Br J Gen Pract 2002;52:972-932.
133. Duffy SW: The controversy over breast cancer screening. Hosp Med 2002;63:708-709.
134. Smith RA, Cokkinides V, Eyre HJ: American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003;53:27-43.
135. Paulson HL: Diagnostic testing in neurogenetics. Principles, limitations, and ethical considerations. Neurol Clin 2002;20:627-643.
136. McConnell LM, Koenig BA, Greely HT, Raffin TA: Genetic testing and Alzheimer disease: Has the time come? Alzheimer Disease Working Group of the Stanford Program in Genomics, Ethics & Society. Nat Med 1998;4:757-759.
137. Roses AD: Genetic testing for Alzheimer disease. Practical and ethical issues. Arch Neurol 1997;54:1226-1229.
138. Post SG, Whitehouse PJ, Binstock RH, Bird TD, Eckert SK, Farrer LA, Fleck LM, et al: The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA 1997;277:832-836.
139. Burke W, Coughlin SS, Lee NC, Weed DL, Khoury MJ: Application of population screening principles to genetic screening for adult-onset conditions. Genet Test 2001;5:201-211.
140. Lichtor T: Gene expression of apolipoprotein E in human brain tumors. Neurosci Lett 1992;138:287-290.
141. Venanzoni MC, Ghiunta S, Muraro GB, et al: Apolipoprotein E expression in localized prostate cancers. Int J Oncol 2003;22:779-786.
142. Fathallah-Shaykh HM, He B, Zhao LJ, Engelhard HH, Cerullo L, Lichtor T, Byrne R, Munoz L, Von Roenn K, Rosseau GL, Glick R, Chen S, Khan F: Genomic expression discovery predicts pathways and opposing functions behind phenotypes. J Biol Chem 2003;278:23830-23833.
143. Bassett LW: Diagnosis of Diseases of the Breast. Philadelphia, WB Saunders, 1997.
144. Parkin DM, et al (eds): Cancer Incidence in Five Continents. Lyon, IARC Scientific Publications, 1992, vol VI, No 120.
145. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
146. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543.
147. Centers for Disease Control: Cancer Statistics 1999: Cancer Incidence. http://www.cdc.gov/cancer/npcr/index.htm.
148. EichnerJE, Dunn ST, Perveen G, Thompsoin DM, Stewart KE, Stroehla BC: Apolipoprotein E polymorphism and cardiovascular disease: A HuGE review. Am J Epidemiol 2002;155:487-495.
149. Kamboh MI, Sephehrnia B, Ferrell RE: Genetic studies of human apolipoproteins. 6. Common polymorphism of apolipoprotein E in blacks. Dis Markers 1989;7:49-55.
150. Nathoo N, Chetry R, van Dellen JR, Connolly C, Naidoo R: Apolipoprotein E polymorphism and outcome after closed traumatic brain injury: Influence of ethnic and regional differences. J Neurosurg 2003;98:302-306.